Tetrahydrocannabivarinic acid (THCVA) is a non-psychoactive cannabinoid and molecular precursor to THCV. THCVA may act an anti-inflammatory, and possibly help regulate the immune system. THCVA holds promise as a pain reliever and key contributor to the potential anti-cancer properties cannabis may offer. THCVA will convert to THCV through decarboxylation, which occurs when cannabis is exposed to heat or sunlight.
Cannabidiolic acid (CBDA) is a non-psychoactive cannabinoid and the acidic precursor to CBD. CBDA can be found in the live or raw form of cannabis, particularly in the hemp plant and strains bred to cultivate higher CBD levels. CBDA converts to CBD through decarboxylation, which occurs when cannabis is exposed to heat or sunlight.
Tetrahydrocannabinolic acid (THCA) is a non-psychoactive cannabinoid and a primary constituent of cured and live cannabis. THCA is the acidic form of THC as they share a very similar molecular composition. The differentiation is due to an additional carboxyl group in THCA, which converts to THC through exposure to heat or sunlight. This process of decarboxylation expedites the conversion when cannabis is subjected to high heat. In its raw form, THCA’s prevalence in cannabis may have a multitude of therapeutic applications due to its non-psychoactive nature.
Cannabichromene (CBC) is a non-psychoactive cannabinoid with a host of potential therapeutic applications. CBC may carry pain relieving properties, act as a potent anti-inflammatory agent, assist with digestive and gastrointestinal disorders, possess antibacterial and antifungal efficacy, and could potentially contribute to the regeneration of brain cells, which possibly has implications in the treatments of multiple sclerosis, fibromyalgia, dementia, Alzheimer’s and other neurodegenerative related conditions.
Cannabinol (CBN) is considered a mildly psychoactive cannabinoid known for its powerful sedative properties. When THC is oxidized, the degradation process converts THC to CBN, which may account for the sedative effect aged cannabis often carries.
Cannabigerol (CBG) is a non-psychoactive cannabinoid that plays an important role in the biochemistry of the cannabis plant. CBG acts as a chemical precursor to other cannabinoids such as THC and CBD.
Tetrahydrocannabivarin (THCV) is a cannabinoid that holds potentially potent psychoactive effects, along with a host of medicinal benefits. Similar in chemical composition to THC, THCV is thought to act as an antagonist to some of the effects of THC when found in small amounts, while possibly accentuating them in higher doses. Strains or products rich in THCV may result in a stimulating, clear headed, almost psychedelic type of energetic high that is typically shorter in duration.
Cannabidiol (CBD) is a non-psychoactive cannabinoid found in cannabis used to treat the symptoms of conditions such as epilepsy, nausea, pain, inflammation, anxiety, depression, neurodegenerative disorders, opioid withdrawal and PTSD. CBD has also demonstrated a potentially pivotal role in battling adverse side effects of chemotherapy and has shown promise in inhibiting growth in certain types of tumors.
Tetrahydrocannabinol (THC) is the primary psychoactive compound in the cannabis plant and widely known for the “high” or “stoned” feeling typically associated with cannabis use. THC can produce a multitude of psychoactive effects, including but not limited to, euphoria, relaxation, introspection, creativity, sedation, sensory alteration, appetite stimulation, focus and energy. Adverse effects may include dry mouth, redness in the eyes, disorientation, dizziness, tachycardia, anxiety and paranoia.
At this point, most people are familiar with THC and equate THC percentage to medical cannabis strength. In actuality, it's a combination of terpenes and cannabinoids such as CBD, THCA, and CBN which work together synergistically to provide various medicinal benefits. Without the joint effort, the magic of cannabis wouldn’t be possible.